What to Expect From a Liver Cancer Blood Test: From Blood Collection to Results
Blog What to Expect From a Liver Cancer Blood Test: From Blood…
Every year, thousands of Americans are diagnosed with liver cancer, often only after symptoms appear. In 2026, an estimated 42,340 Americans are expected to be diagnosed with liver cancer, while nearly 30,980 people may die from the disease. Despite advances in treatment, liver cancer remains one of the least screened cancers in the United States.
As liver cancer rates continue to rise, the need for the early detection of liver cancer has become more important than ever. Companies like MoleculeDx are helping address this challenge through innovative blood-based testing technology designed for earlier diagnosis.
Imagine a 65-year-old man with fatty liver disease who feels perfectly healthy. Without obvious symptoms, liver cancer can quietly develop for years. By the time it is discovered, treatment options may be limited. This is why awareness and early detection matter more than ever.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 75–85% of all primary liver cancer cases worldwide. It begins in liver cells called hepatocytes and usually develops after years of chronic liver damage.
Many people have never heard of hepatocellular carcinoma until they or a loved one receive a diagnosis. Yet understanding HCC is important because it represents the vast majority of liver cancer cases.
Several conditions can increase the risk of HCC, including:
Hepatitis B infection
Hepatitis C infection
Cirrhosis
Fatty liver disease (NAFLD/NASH)
Obesity and diabetes
Heavy alcohol consumption
Early-stage HCC often causes no symptoms. As the disease progresses, symptoms may include:
Unexplained weight loss
Fatigue
Abdominal pain or swelling
Loss of appetite
Jaundice (yellowing of the skin or eyes)
Because symptoms appear late, many patients are diagnosed only after the cancer has advanced.
Liver cancer remains a major public health concern in the United States.
42,340 new liver cancer cases are expected in 2026.
30,980 deaths are projected from liver cancer.
The median age at diagnosis is 68 years.
The overall five-year survival rate is approximately 22%.
Unlike many other cancers, liver cancer rates have increased over recent decades due to chronic liver disease and changing lifestyles.
One of the strongest predictors of survival is how early the cancer is detected.
Stage I (Localized): 36% five-year survival
Stage II/III (Regional): 14% five-year survival
Stage IV (Distant): 4% five-year survival
These numbers make one thing clear: early detection saves lives.
States with historically higher liver cancer incidence include:
Texas
Hawaii
California
Louisiana
Mississippi
New Mexico
Alaska
Arizona
Washington
Florida
Differences in hepatitis prevalence, obesity rates, alcohol use, and healthcare access may contribute to these variations.
Yes. Men are two to three times more likely than women to develop liver cancer.
Adults aged 60 years and older face the highest risk, with most diagnoses occurring between ages 65 and 74.
Research shows higher liver cancer rates among:
Asian Americans
Hispanic Americans
Yes. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly recognized as major drivers of liver cancer in the U.S.
Several factors are contributing to rising liver cancer rates:
Increasing obesity
Diabetes
Fatty liver disease
Chronic hepatitis infections
Aging populations
Limited screening programs
Unlike many cancers whose rates have declined, liver cancer continues to present a growing challenge.
The numbers are striking.
Patients diagnosed at Stage I have a 36% five-year survival rate, while those diagnosed at Stage IV have only a 4% five-year survival rate.
Unfortunately, there is currently no standard nationwide screening program for liver cancer among average-risk adults. As a result, many cases are detected too late, reducing treatment options and survival chances.
Improving access to early detection could help change these outcomes.
MoleculeDx is working to make liver cancer screening more accessible through blood-based testing technology designed for earlier detection.
According to the company, its technology offers:
Up to 95% accuracy
Detection of Stage I & II liver cancer
At-home blood sample collection
Results within 24 hours
Liquid biopsy technology
No hospital visit required
By identifying liver cancer earlier, technologies like these may help patients access treatment sooner and improve outcomes.
Liver cancer often develops silently, making early detection critical. MoleculeDx offers blood-based liver cancer detection with up to 95% accuracy, Stage I & II detection, at-home sample collection, and results within 24 hours.
Ready to take control of your liver health? Book your MoleculeDx liver cancer detection test today.
Book Your Test Now → https://moleculedx.com/
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 75–85% of all primary liver cancer cases.
Yes. Rising obesity, fatty liver disease, and chronic hepatitis infections have contributed to increasing liver cancer rates in the United States.
People with hepatitis B or C, cirrhosis, fatty liver disease, diabetes, obesity, or a family history of liver disease may benefit from discussing screening with their healthcare provider.
Early-stage liver cancer has a much higher survival rate. Detecting cancer at Stage I can significantly improve outcomes compared with diagnosis at advanced stages.
According to the company, MoleculeDx’s liver cancer detection technology offers up to 95% accuracy for early detection.
Yes. Liver cancer often develops silently, especially in its early stages, which is why awareness and screening are important.
When detected early, hepatocellular carcinoma may be treated more effectively through surgery, transplantation, or other therapies. Outcomes are generally better when diagnosed at an earlier stage.
Sources: American Cancer Society (ACS), National Cancer Institute (NCI) SEER Program, Centers for Disease Control and Prevention (CDC), and MoleculeDx.
read more about moleculeDX:https://www.moleculedx.com/can-liver-cancer-be-detected-by-blood-test/
Blog What to Expect From a Liver Cancer Blood Test: From Blood…
Blog Liver Cancer Blood Markers: What Do They Tell Us? Blood tests…
Blog 5 Benefits of Regular Liver Cancer Surveillance for People at High…
Developing blood-based molecular tests for cancer detection. Powered by Fusion-detect™ technology.
© 2026 MoleculeDx Inc. All rights reserved.
Test results should be interpreted in the context of other clinical information and are not a substitute for evaluation by a qualified healthcare provider.